You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Skip to content

Orenitram 90-Day Trial Program terms & conditions

The Orenitram 90-Day Trial Program (“Trial Program”) is offered by United Therapeutics Corporation. To utilize this Trial Program, you must have a valid prescription for an FDA-approved use of Orenitram. There is no obligation to continue Orenitram after the 90-Day Trial Program. If the decision is made to continue therapy, a separate prescription must be written by your healthcare provider and dispensed by one of United Therapeutics Corporation’s contracted specialty pharmacies, Accredo or CVS Specialty. Patients may be offered the Trial Program exclusively through their healthcare provider.

Terms & conditions for trial program

By enrolling in the 90-Day Trial Program for Orenitram, you acknowledge that you currently meet the eligibility criteria and will comply with the Terms and Conditions described below:

  1. Only new patients with a valid prescription for an FDA-approved use of Orenitram may use this Trial Program. This Trial Program is not valid for patients transitioning to Orenitram from Tyvaso or Remodulin. By enrolling in this Trial Program, you
 certify that: (a) you are not currently using or have previously used Orenitram, and (b) you are not transitioning to Orenitram
 from Tyvaso or Remodulin.
  2. Patients are not eligible to start the Trial program in the hospital setting (ie, “Inpatient”).
  3. Product cannot be shipped to a hospital, physician’s office, etc. Product must be shipped directly to the patient.
  4. This offer is only valid for those patients 18 years and older.
  5. Only 1 enrollment per patient may be redeemed under this program; no photocopies or reproductions of the enrollment form will be accepted.
  6. Enrollment is valid for 90 days of Orenitram at no cost to the patient.
  7. No claim for reimbursement for product dispensed pursuant to this Trial Program may be submitted, in whole or part,
 to any third-party payer, including a public or private payer.
  8. The prescription for the Trial Program cannot be submitted to count towards out-of-pocket costs under any prescription
 medicine plan.
  9. For Medicare patients, Trial Program product may not count towards “True Out-of-Pocket (TrOOP)” expenses.
  10. The Trial Program enrollment form will be accepted only at United Therapeutics Corporation’s contracted pharmacy for this Program, Lash and Group. Offer not valid if submitted to any other pharmacy.
  11. This enrollment form is not transferable. It is illegal for any person to sell, purchase, or trade, or offer to sell, purchase, or trade or to counterfeit this enrollment form.
  12. This 90-Day Trial Program cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription.
  13. This free trial is not health insurance.
  14. United Therapeutics Corporation makes no express or implied guarantee that Orenitram will be covered by any third-party payer after the 90-day trial period.
  15. Offer good only in the United States and Puerto Rico.
  16. United Therapeutics Corporation reserves the right to rescind, revoke, or amend this free trial program at any time
 without notice.

Important Safety Information

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

Adverse Reactions

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven, placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

Drug Interactions

  • Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

Specific Populations

  • Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
  • It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
  • Safety and effectiveness of Orenitram in pediatric patients have not been established.
  • Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

Indication

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

OREISIhcpOCT19

Please see Full Prescribing Information and Patient Information for Orenitram.

For additional information, call 1-877-UNITHER (1-877-864-8437).

The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals.

Important Safety Information

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

Adverse Reactions

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven, placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

Drug Interactions

  • Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

Specific Populations

  • Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
  • It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
  • Safety and effectiveness of Orenitram in pediatric patients have not been established.
  • Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

Indication

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

OREISIhcpOCT19

Please see Full Prescribing Information and Patient Information for Orenitram.

For additional information, call 1-877-UNITHER (1-877-864-8437).